Lapatinib, a dual EGFR and HER2 inhibitor, are clinically effective against HER2-amplified breast cancer by blocking HER2 phosphorylation, resulting in inhibition of downstream PI3K/AKT and MAPK pathways [36]. The gene discussed is PIK3CA; the disease is breast cancer.